Highlighted text has been updated as of December 17, 2024. The PARAGON-HF trial failed to show that sacubitril/valsartan reduced adverse events among patients with HFpEF. Patients with HFpEF were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback